Efficacy and Safety of Telitacicept Combined With Tofacitinib for Refractory Rheumatoid Arthritis
- Sponsor
- Zhejiang Provincial People's Hospital
- Study ID
- NCT06979271
- Status
- Recruiting
Conditions
- Rheumatoid Arthritis
- Telitacicept
- Treatment Compliance
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 85 Years
- Healthy Volunteers
- Not accepted
Interventions
- Telitacicept Tofacitinib — DRUGOne group of D2TRA subjects receive Telitacicept combine Tofacitinib treatment
Study Details
The aim of this study is to observe the clinical efficacy and safety of telitacicept combined with tofacitinib in the treatment of D2TRA patients
Key Dates
- Start date
- Jun 1, 2025
- Status verified
- May 2025
- Primary completion
- Apr 30, 2026
- Completion
- Apr 30, 2027
Study Design
- Enrollment
- 20 participants (estimated)
Primary Outcome Measure
Efficacy of Telitacicept Combined With Tofacitinib for Refractory Rheumatoid Arthritis [ Time Frame: maximum 1 years ]
Related Studies
- CorEvitas Rheumatoid Arthritis (RA) Drug Safety & Effectiveness RegistryEnrolling By Invitation · CorEvitas · Waltham, Massachusetts
- Physica System Total Knee Replacement Registry StudyRecruiting · Limacorporate S.p.a · Rancho Mirage, California
- Early Rheumatoid Arthritis Lung Disease StudyRecruiting · University of Nebraska · Omaha, Nebraska
- Maternal Autoimmune Disease Research Alliance (MADRA) RegistryRecruiting · Duke University · Durham, North Carolina